In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
News|Podcasts|June 25, 2026
ACT Brief: DIA Leadership Amid Uncertainty, Reimagining CRO Contracts, and Eli Lilly Expansion
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine regulatory uncertainty and 2026 breakthroughs shaping clinical research, reimagining CRO contracting models for financial transparency, and Eli Lilly's acquisition strategy.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- At the 2026 DIA Global Annual Meeting, Marwan Fathallah, president and CEO of DIA Global,
discussed ecosystem-wide leadership amid regulatory uncertainty and highlighted breakthroughs in obesity, healthcare AI, and cell and gene therapy shaping the field in 2026. - In a new contributed article, authors
examined how traditional CRO contracting models create financial misalignment and proposed the CURED Shared Performance Contracting model, which aligns effort to deliverables through transparent cost tracking, progress monitoring, and risk sharing to improve revenue recognition and margin stability. - Eli Lilly entered a strategic research
collaboration with Abbisko Therapeutics for early-stage drug discovery across multiple targets. The deal follows Lilly's acquisitions this year of Contessa Pharmaceuticals for sleep disorders and Ajax Therapeutics for a selective JAK2 inhibitor.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research.
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools.
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.
Trending on Applied Clinical Trials Online
1
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
2
How a Platform Approach Can Scale AI’s Impact in Life Sciences
3
DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5